GlassScriptPhysician profile
Nisha Lakhani
NPI 1336158609
$7,493.70
in general payments reported to CMS, 2019-2025
35 companies · $2,061 in 2025
The $2,061 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $286 · 2020: $359 · 2021: $675 · 2022: $1,063 · 2023: $1,261 · 2024: $1,789 · 2025: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,061 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,061.07 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,250.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $868.38 | 2021-2025 | |
| Novo Nordisk INC | $693.67 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $644.48 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $535.25 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $505.26 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.02 | 2020-2025 | Xifaxan |
| Pfizer INC. | $402.10 | 2020-2025 | |
| Amgen INC. | $226.87 | 2022-2025 | Repatha, Otezla, Tepezza |
| Currax Pharmaceuticals LLC | $174.54 | 2021-2023 | Nexletol, Onzetra Xsail, Contrave |
| Novartis Pharmaceuticals Corporation | $174.13 | 2022-2025 | |
| Arbor Pharmaceuticals, INC. | $173.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $130.07 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.41 | 2022-2025 | |
| Exact Sciences Corporation | $125.33 | 2024-2025 | Cologuard Collection Kit |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $123.37 | 2023-2025 | Tyrvaya, Ryzumvi |
| Azurity Pharmaceuticals, INC. | $113.25 | 2023-2025 | Horizant, Edarbi, Adthyza |
| Harrow Eye, LLC | $103.79 | 2024-2025 | Vevye |
| Janssen Pharmaceuticals, INC | $86.46 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $82.08 | 2020-2022 | |
| Idorsia Pharmaceuticals US INC | $81.22 | 2022-2023 | Quviviq |
| Abbott Laboratories | $60.59 | 2022-2023 | Freestyle Libre |
| Astellas Pharma US INC | $57.73 | 2025 | Veozah |
| Bausch & Lomb Americas INC. | $55.06 | 2023-2024 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $36.02 | 2022-2024 | Rocklatan |
| Upsher-Smith Laboratories LLC | $26.33 | 2020 | |
| Sanofi-Aventis U.S. LLC | $22.62 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.37 | 2025 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $18.12 | 2022 | |
| Acadia Pharmaceuticals INC | $17.53 | 2024 | Nuplazid |
| Phadia US INC. | $16.57 | 2025 | Immunocap |
| Ibsa Pharma INC. | $15.27 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.78 | 2020 | |
| Phathom Pharmaceuticals, INC. | $11.97 | 2025 | Voquezna |
| Eisai INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisha Lakhani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.